SAFETY AND EFFICACY OF RUXOLITINIB (RUX) IN PATIENTS WITH MYELOFIBROSIS (MF) WHO STARTED TREATMENT AT 10mg BID AND HAD THE DOSE UPTITRATED IN THE PHASE 3B EXPANDED-ACCESS JUMP STUDY
HAEMATOLOGICA(2017)
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined